Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

60 Degrees Pharmaceuticals receives Nasdaq delisting notice, plans reverse split

60 Degrees Pharmaceuticals receives Nasdaq delisting notice, plans reverse split

60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP) has received a Nasdaq delisting notice, indicating the company is not compliant with the minimum bid price requirement. This determination followed the company's listed securities falling below $1.00 per share for 30 consecutive business days between October 8, 2026 and November 18, 2026, as reported in a recent SEC filing.

The company has previously undergone reverse stock splits, resulting in an overall reverse split ratio of 1-for-20. As a result, Nasdaq will delist SXTP's securities unless the company files an appeal by November 27, 2026. If no appeal is made, the delisting and suspension of trading at the opening of business on December 1, 2026, will take effect.

The company has requested a hearing before a Nasdaq Hearings Panel and paid the associated $20,000 fee, which will stay the suspension and delisting process pending the panel's decision. In response, 60 Degrees Pharmaceuticals plans to effect another reverse stock split of its common stock, effective December 2, 2026, at which point shares will begin trading under the same symbol but with a new CUSIP number.

The company anticipates that the split-adjusted share price will meet Nasdaq's requirements and the reverse split will be completed as planned. However, there is no guarantee of this outcome, as the panel may deny continued listing.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at investing.com →